Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-24 @ 11:49 PM
NCT ID:
NCT05373251
Eligibility Criteria:
Inclusion Criteria:
* Patients with locally advanced H\&N squamous cell carcinoma or nasopharyngeal cancer undergoing definitive radiation and/or chemoradiotherapy with curative intent at BC Cancer
* Folowing subsites included: paranasal sinus, nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx.
* Patients willing to undergo study specific fresh biopsy of the tumour, and/or metastatic nodal site at baseline and at recurrence, and a blood test for genomic analysis.
* ECOG PS 0-2
* Age \>/=18 years
* Primary tumour or regional lymph nodes that are amenable to core biopsy and sufficient sampling for POG purposes
* Measurable disease
* Adequate organ function
* Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form)
* Willingness to be contacted for future studies based on the data that is generate; included in this is the anticipation that patient would be fit or a candidate for clinical trials
Exclusion Criteria:
* • Primary skin, salivary gland and thyroid malignancies
* Unwilling/unable to undergo biopsies and blood tests
* Patients undergoing adjuvant radiotherapy after definitive surgery without gross residual disease
* Patients with estimated life expectancy less than 12 months
* Patients who have received prior chemoradiotherapy within the past 12 months
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT05373251
Study Brief:
Protocol Section:
NCT05373251